Mycophenolate Mofetil Hexal

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Hexal, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is used to prevent acute rejection in solid organ transplantation and to treat selected autoimmune kidney disorders, such as lupus nephritis, in adult patients. Therapy is typically managed by transplant physicians and nephrologists.

GNH USA supplies Mycophenolate Mofetil Hexal as a licensed, GDP‑compliant international pharmaceutical supplier, providing reliable product availability to hospitals, transplant centres, specialty pharmacies and clinical procurement teams worldwide.

Mycophenolate Mofetil is an antimetabolite immunosuppressant that inhibits lymphocyte proliferation in transplant and autoimmune disease settings. - Solid organ transplantation: prevents acute rejection and supports graft survival. - Lupus nephritis: reduces renal inflammation and preserves kidney function. - Proliferative glomerulonephritis: controls disease activity and slows progression.

Mycophenolate Mofetil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain. - Infections: increased susceptibility to bacterial, viral, or fungal infections. - Hematologic changes: anemia, leukopenia, or thrombocytopenia. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increases in transaminases. - Fever: low‑grade fever may occur. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain disease. - Malignancy: increased risk of post‑transplant lymphoproliferative disorder. - Bone marrow failure: aplastic anemia or pancytopenia. - Reproductive